Category: Health Care

The Rarity of Dr. Jennifer Walden

Dr. Jennifer Walden is one of the most successful cosmetic surgeons in her field. She is also one of the rare female surgeons. This is an interesting deal. While there are quite a few female doctors, it is rare for them to go into cosmetic plastic surgery. Dr. Walden herself has admitted this interesting phenomenon. However, she has shown that women can be every bit as good as men when it comes to cosmetic surgery. She has shown so much skill in this field that she has gained a lot of recognition as a cosmetic surgeon. One of the main reasons for her success is that she is very passionate about her work as a surgeon and learn more about Jennifer.


Jennifer Walden has talked a lot about how rare it is for a woman to become a cosmetic surgeon. She has stated that out of more than 8,000 surgeons, there are only 851 that are women. This is quite an amazing statistic. She also went on to say that only a dozen of female cosmetic surgeons live in Austin Texas. However, Jennifer has shown that she is very efficient in what she does as a surgeon. She is one of the surgeons that people seek out in order to get cosmetic work done and read full article.


Dr. Walden has studied very hard in the subject of cosmetic surgery. She has taken in a ton of knowledge about the practice and all of the different topics that are related to medicine. She has used the knowledge that she has gained in order to not only bring forth some new methods for cosmetic surgery but to also bring back another form of surgery with the use of silicon. Jennifer has shown that she is passionate enough to go beyond what she knows about the practice and actually come up with new and more effective methods.

Other Reference:

Molly He Joins Jim Tananbaum and His Team at Foresite Capital Management

Late April 2017, Foresite Capital reavealed that Dr. Molly He would join Foresite Capital as a venture partner. Molly has vast experience in genomic and pharmaceutical research and development, which spans for over 15 years. Additionally, she previously worked at Illumina as the senior director.

Jim Tananbaum, the CEO and M.D of Foresite Capital, praised Dr. He as one of the most acclaimed scientific researchers in next-generation sequencing. He also reiterated that her vast expertise in drug development and genomics, as well as tremendous leadership track record are useful resources to Foresite. In fact, her skills would be helpful to the company, especially in its endeavors to diversify and expand its portfolio of transformational entities.

At Illumina, Dr. He was tasked with the role of overseeing the company’s worldwide protein reagent enhancements and innovations. Before joining Illumina, she worked at Pacific Biosciences as the head of protein sciences. In the earlier stages of her career, Molly He spent about a decade in the pharmaceutical industry. Aside from her Ph.D. in protein biophysics from LA-based University of California, Molly holds a biochemistry degree from Nankai University.

Jim Tananbaum

Jim Tananbaum has created a name for himself in the corporate circles due to his numerous achievements. He holds vast experience spanning for more than two decades, especially in creating healthcare companies. Currently, he is the founder and CEO of Foresite Capital, which has about $1.1 billion in terms of assets under management. Foresite Capital Management combines the healthcare specialization with the best practices of growth investing. Since the company’s establishment, it has been investing in companies with late-stage, disruptive services and products in various sectors of healthcare such as diagnostics and genomics. More details can be found on LinkedIn.

As per Ideamensch, Before the inception of Foresite, Tananbaum served as the CEO and founder of Theravance. He was also a founding partner of Prospect Venture Partners II and III. Early in promising his career, Jim served at Sierra Ventures as a partner. In fact, he played a significant role in the inception of the company’s healthcare service investment practice. Jim is also acknowledged for leading other numerous investments including Jazz Pharmaceuticals (IPO), Healtheon, Amerigroup (IPO), and Amira Phramaceuticals.

You can visit his Crunchbase profile: